Premium
Effectiveness of Nadolol in a Clinic Population of Migrainous Patients
Author(s) -
Medina José L.,
Medina José L.
Publication year - 1988
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1988.hed2802099.x
Subject(s) - nadolol , migraine , medicine , headaches , population , anesthesia , pediatrics , surgery , propranolol , environmental health
SYNOPSIS An uncontrolled 15‐month prospective study was conducted in a clinic population of 116 migrainous patients who received 20–240 mg. of nadolol dally (average = 46.9 mg) for 1–15 months (average = 7.0 months). The 116 patients were classified into: Group A ‐ 33 patients who partially responded to proprenolol who were switched to nadolol; Group B ‐ 48 patients with mixed migraine and muscle contraction headache who had partially responded to antidepressants; and Group C ‐ 35 new patients who were treated with nadolol. Eleven patients were lost to follow‐up. In Group A, 3 patients did equally well on both medication, 19 (61.2%) did better on nadolol, and 7 (22.5%) did worse. In Group B, 21 patients (45.7%) responded to nadolol and in Group C, 21 (75.0%). It took an average of 3 months before nadolol achieved complete control of the headaches in 17 patients. Response to nadolol could not be linked with beta blockade and the daily dose required was low (average = 39.7 mg.). This study suggests that nadolol is effective and safe in the long‐term therapy of migraine and may become more effectual with time. Its spectrum of efficacy includes simple migraine headaches, and the less responsive, intricate types of migrainous headaches of the Headache Clinic population.